Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Onapristone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR known ✓ | P06401 | 13/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 11/20 | 1.00 |
| ▸ | AR | P10275 | 8/20 | 1.00 |
| ▸ | NR3C2 | P08235 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.69 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.69 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.69 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.69 |
| ▸ | ESR1 | P03372 | 3/20 | 0.69 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.69 |
| ▸ | LMNA | P02545 | 2/20 | 0.69 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.69 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.69 |
| ▸ | TP53 | P04637 | 1/20 | 0.69 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.69 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.69 |
| ▸ | THPO | P40225 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Onapristone SCHEMBL9738693 | 1.00 | PGR (1.00) | PGRNR3C1ARNR3C2CYP3A4 | |
| Onapristone SCHEMBL1649697 | 1.00 | PGR (1.00) | PGRNR3C1ARNR3C2CYP3A4 | |
| Onapristone SCHEMBL14666146 | 1.00 | PGR (1.00) | PGRNR3C1ARNR3C2CYP3A4 | |
| Onapristone SCHEMBL9170610 | 1.00 | PGR (1.00) | PGRNR3C1ARNR3C2CYP3A4 | |
| Onapristone SCHEMBL6670566 | 1.00 | PGR (1.00) | PGRNR3C1ARNR3C2CYP3A4 | |
| Onapristone SCHEMBL24910667 | 1.00 | PGR (1.00) | PGRNR3C1ARNR3C2CYP3A4 | |
| Onapristone SCHEMBL9558688 | 1.00 | PGR (1.00) | PGRNR3C1ARNR3C2CYP3A4 | |
| Onapristone SCHEMBL9558898 | 1.00 | PGR (1.00) | PGRNR3C1ARNR3C2CYP3A4 | |
| Onapristone SCHEMBL21740378 | 1.00 | PGR (1.00) | PGRNR3C1ARNR3C2CYP3A4 | |
| Onapristone SCHEMBL14870640 | 1.00 | PGR (1.00) | PGRNR3C1ARNR3C2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 29870 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4748859-A2 | CHEMICALLY AND PHOTOCHEMICALLY INITIATED CELL MEMBRANE BLEBBING TO INDUCE CELL VESICLE PRODUCTION, MODIFICATIONS THEREOF, AND USES THEREOF | The Regents of the University of California (US) | 2026-05-27 | — | — | EP | claimed |
| US-20260116861-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-04-30 | — | — | US | claimed |
| EP-4680203-A1 | COMPOSITIONS FOR SUSTAINED RELEASE OF POORLY SOLUBLE ACTIVE INGREDIENTS | Prolevi Bio AB (SE) | 2026-01-21 | — | — | EP | claimed |
| EP-4676544-A1 | ANTIBODY-DRUG CONJUGATE COMPRISING ANTIBODIES AGAINST HUMAN L1CAM AND USES THEREOF | LigaChem Biosciences Inc. (KR) | 2026-01-14 | — | — | EP | claimed |
| US-12522572-B2 | Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-01-13 | — | — | US | claimed |
| US-20260007763-A1 | PEGYLATED ANTIBODY HYDROXYL-BEARING DRUG CONJUGATE | SHENZHEN ENDURING BIOTECH, LTD. (CN) | 2026-01-08 | — | — | US | claimed |
| WO-2025233679-A1 | COMPOSITIONS AND METHODS RELATED TO A COMBINATION THERAPY OF STING AGONISTS AND ANTIBODY DRUG CONJUGATES | LIGACHEM BIOSCIENCES INC. (KR) | 2025-11-13 | — | — | WO | claimed |
| WO-2025233682-A1 | ANTIBODY DRUG CONJUGATES COMPRISING STING AGONISTS AND USES THEREOF | LIGACHEM BIOSCIENCES INC. (KR) | 2025-11-13 | — | — | WO | claimed |
| EP-4637751-A2 | FOXM1 INHIBITORS AND THEIR USE IN TREATING CANCERS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2025-10-29 | — | — | EP | claimed |
| US-20250276084-A1 | HYDROPHILIC LINKERS AND CONJUGATES THEREOF | GLYKOS FINLAND OY (FI) | 2025-09-04 | — | — | US | claimed |
| US-4888331-A | SIDE EFFECT REDUCTION; | SCHERING AKTIENGESELLSCHAFT (DE) | 1989-12-19 | — | — | US | claimed |
| US-4879285-A | PLATELET ACTIVATING FACTOR | ROYAL NORTH SHORE HOSPITAL AND AREA HEALTH SERVICE (AU) | 1989-11-07 | — | — | US | claimed |
| US-4870067-A | Oxytocins and antigestagens in combination for induction of birth | SCHERING AKTIENGESELLSCHAFT (DE) | 1989-09-26 | — | — | US | claimed |
| EP-0310541-A1 | Antigestagenic and antioestrogenic compounds for the introduction of labour and interruption of pregnancy, as well as for the treatment of gynecologic disorders | SCHERING AKTIENGESELLSCHAFT (DE) | 1989-04-05 | — | — | EP | claimed |
| EP-0310542-A1 | Antigestagenic and antioestrogenic compounds for the treatment of hormone-dependent tumours | SCHERING AKTIENGESELLSCHAFT (DE) | 1989-04-05 | — | — | EP | claimed |
| US-4780461-A | ANTIGESTAGENS | SCHERING AKTIENGESELLSCHAFT (DE) | 1988-10-25 | — | — | US | claimed |
| US-4764513-A | IN VITRO FERTILIZATION | SCHERING AKTIENGESELLSCHAFT (DE) | 1988-08-16 | — | — | US | claimed |
| EP-0266303-A2 | Antigestagens for the inhibition of uterine prostaglandin synthesis | SCHERING AKTIENGESELLSCHAFT (DE) | 1988-05-04 | — | — | EP | claimed |
| EP-0261798-A2 | Fertility control | O'Neill, Christopher (AU) | 1988-03-30 | — | — | EP | claimed |
| EP-0214924-A2 | Oxytocin and antigestagene for the induction of labour | SCHERING AKTIENGESELLSCHAFT (DE) | 1987-03-18 | — | — | EP | claimed |